Generic Name and Formulations:
Tropicamide 0.5%, 1%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for MYDRIACYL:
For mydriasis and cycloplegia for diagnostic procedures.
Adults and Children:
For refraction: instill 1–2 drops of 1% soln in the eye(s); repeated in 5 minutes. An additional drop may be instilled if patient is not seen within 20–30 minutes. For examination of fundus: instill 1–2 drops of 0.5% soln 15 or 20 minutes prior to exam. Lacrimal sac should be compressed by digital pressure for 2–3 minutes after instillation to reduce excessive systemic absorption.
Remove contact lenses before use. Pregnancy (Cat.C). Nursing mothers.
May interfere with antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Ocular (eg, stinging, blurred vision, photophobia, superficial punctuate keratitis, transient elevation of intraocular pressure), dry mouth, tachycardia, headache, allergic reactions, GI upset, pallor, CNS disturbances (esp. in children).
Soln 0.5%—15mL; 1%—3mL, 15mL
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC